vs

Side-by-side financial comparison of INTERPARFUMS INC (IPAR) and MYRIAD GENETICS INC (MYGN). Click either name above to swap in a different company.

INTERPARFUMS INC is the larger business by last-quarter revenue ($386.2M vs $209.8M, roughly 1.8× MYRIAD GENETICS INC). On growth, INTERPARFUMS INC posted the faster year-over-year revenue change (6.8% vs -0.4%). Over the past eight quarters, INTERPARFUMS INC's revenue compounded faster (9.2% CAGR vs 1.9%).

Inter Parfums Inc is a global prestige fragrance firm that develops, manufactures and distributes perfumes, body care and related cosmetics. It partners with top luxury fashion and lifestyle brands to launch licensed fragrance lines, serving consumers across North America, Europe, Asia Pacific and other key markets via department stores, beauty retailers and official e-commerce channels.

Myriad Genetics, Inc. is an American genetic testing and precision medicine company based in Salt Lake City, Utah, United States. Myriad employs a number of proprietary technologies that permit doctors and patients to understand the genetic basis of human disease and the role that genes play in the onset, progression and treatment of disease. This information is used to guide the development of new products that assess an individual's risk for developing disease later in life, identify a pati...

IPAR vs MYGN — Head-to-Head

Bigger by revenue
IPAR
IPAR
1.8× larger
IPAR
$386.2M
$209.8M
MYGN
Growing faster (revenue YoY)
IPAR
IPAR
+7.2% gap
IPAR
6.8%
-0.4%
MYGN
Faster 2-yr revenue CAGR
IPAR
IPAR
Annualised
IPAR
9.2%
1.9%
MYGN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IPAR
IPAR
MYGN
MYGN
Revenue
$386.2M
$209.8M
Net Profit
$28.1M
Gross Margin
61.5%
70.0%
Operating Margin
7.1%
-2.7%
Net Margin
7.3%
Revenue YoY
6.8%
-0.4%
Net Profit YoY
16.0%
EPS (diluted)
$0.88
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IPAR
IPAR
MYGN
MYGN
Q4 25
$386.2M
$209.8M
Q3 25
$429.6M
$205.7M
Q2 25
$333.9M
$213.1M
Q1 25
$338.8M
$195.9M
Q4 24
$361.5M
$210.6M
Q3 24
$424.6M
$213.3M
Q2 24
$342.2M
$211.5M
Q1 24
$324.0M
$202.2M
Net Profit
IPAR
IPAR
MYGN
MYGN
Q4 25
$28.1M
Q3 25
$65.8M
$-27.4M
Q2 25
$32.0M
$-330.5M
Q1 25
$42.5M
$-100.0K
Q4 24
$24.2M
Q3 24
$62.3M
$-22.1M
Q2 24
$36.8M
$-36.7M
Q1 24
$41.0M
$-26.0M
Gross Margin
IPAR
IPAR
MYGN
MYGN
Q4 25
61.5%
70.0%
Q3 25
63.5%
69.9%
Q2 25
66.2%
71.2%
Q1 25
63.7%
68.5%
Q4 24
64.5%
71.7%
Q3 24
63.9%
70.2%
Q2 24
64.5%
69.6%
Q1 24
62.5%
68.1%
Operating Margin
IPAR
IPAR
MYGN
MYGN
Q4 25
7.1%
-2.7%
Q3 25
25.3%
-11.3%
Q2 25
17.7%
-154.5%
Q1 25
22.2%
-14.8%
Q4 24
10.0%
-18.6%
Q3 24
25.0%
-9.4%
Q2 24
18.9%
-17.3%
Q1 24
21.0%
-13.8%
Net Margin
IPAR
IPAR
MYGN
MYGN
Q4 25
7.3%
Q3 25
15.3%
-13.3%
Q2 25
9.6%
-155.1%
Q1 25
12.5%
-0.1%
Q4 24
6.7%
Q3 24
14.7%
-10.4%
Q2 24
10.8%
-17.4%
Q1 24
12.7%
-12.9%
EPS (diluted)
IPAR
IPAR
MYGN
MYGN
Q4 25
$0.88
$-0.09
Q3 25
$2.05
$-0.29
Q2 25
$0.99
$-3.57
Q1 25
$1.32
$0.00
Q4 24
$0.78
$-0.47
Q3 24
$1.93
$-0.24
Q2 24
$1.14
$-0.41
Q1 24
$1.27
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IPAR
IPAR
MYGN
MYGN
Cash + ST InvestmentsLiquidity on hand
$137.1M
$149.6M
Total DebtLower is stronger
$176.0M
$119.9M
Stockholders' EquityBook value
$880.7M
$368.0M
Total Assets
$1.6B
$706.6M
Debt / EquityLower = less leverage
0.20×
0.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IPAR
IPAR
MYGN
MYGN
Q4 25
$137.1M
$149.6M
Q3 25
$77.5M
$145.4M
Q2 25
$53.9M
$74.4M
Q1 25
$75.3M
$91.8M
Q4 24
$109.3M
$102.4M
Q3 24
$78.8M
$99.9M
Q2 24
$37.7M
$97.3M
Q1 24
$76.1M
$104.3M
Total Debt
IPAR
IPAR
MYGN
MYGN
Q4 25
$176.0M
$119.9M
Q3 25
$119.5M
Q2 25
Q1 25
Q4 24
$157.3M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
IPAR
IPAR
MYGN
MYGN
Q4 25
$880.7M
$368.0M
Q3 25
$870.9M
$372.8M
Q2 25
$839.4M
$388.1M
Q1 25
$788.6M
$704.9M
Q4 24
$744.9M
$701.1M
Q3 24
$778.5M
$731.7M
Q2 24
$717.1M
$740.5M
Q1 24
$708.1M
$760.0M
Total Assets
IPAR
IPAR
MYGN
MYGN
Q4 25
$1.6B
$706.6M
Q3 25
$1.6B
$728.1M
Q2 25
$1.6B
$677.3M
Q1 25
$1.4B
$1.0B
Q4 24
$1.4B
$1.0B
Q3 24
$1.5B
$1.1B
Q2 24
$1.4B
$1.1B
Q1 24
$1.3B
$1.1B
Debt / Equity
IPAR
IPAR
MYGN
MYGN
Q4 25
0.20×
0.33×
Q3 25
0.32×
Q2 25
Q1 25
Q4 24
0.21×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IPAR
IPAR
MYGN
MYGN
Operating Cash FlowLast quarter
$146.5M
$10.6M
Free Cash FlowOCF − Capex
$145.0M
FCF MarginFCF / Revenue
37.5%
Capex IntensityCapex / Revenue
0.4%
Cash ConversionOCF / Net Profit
5.21×
TTM Free Cash FlowTrailing 4 quarters
$190.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IPAR
IPAR
MYGN
MYGN
Q4 25
$146.5M
$10.6M
Q3 25
$63.9M
$21.1M
Q2 25
$11.9M
$-13.6M
Q1 25
$-7.4M
$-16.3M
Q4 24
$138.0M
$6.6M
Q3 24
$76.1M
$700.0K
Q2 24
$25.5M
$2.6M
Q1 24
$-52.0M
$-18.6M
Free Cash Flow
IPAR
IPAR
MYGN
MYGN
Q4 25
$145.0M
Q3 25
$57.6M
Q2 25
$-3.3M
Q1 25
$-8.8M
Q4 24
$136.1M
Q3 24
$75.4M
Q2 24
$24.4M
Q1 24
$-53.0M
FCF Margin
IPAR
IPAR
MYGN
MYGN
Q4 25
37.5%
Q3 25
13.4%
Q2 25
-1.0%
Q1 25
-2.6%
Q4 24
37.7%
Q3 24
17.8%
Q2 24
7.1%
Q1 24
-16.4%
Capex Intensity
IPAR
IPAR
MYGN
MYGN
Q4 25
0.4%
Q3 25
1.5%
Q2 25
4.5%
Q1 25
0.4%
Q4 24
0.5%
Q3 24
0.2%
Q2 24
0.3%
Q1 24
0.3%
Cash Conversion
IPAR
IPAR
MYGN
MYGN
Q4 25
5.21×
Q3 25
0.97×
Q2 25
0.37×
Q1 25
-0.17×
Q4 24
5.69×
Q3 24
1.22×
Q2 24
0.69×
Q1 24
-1.27×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IPAR
IPAR

European Based Operations$232.7M60%
United States Based Operations$155.2M40%

MYGN
MYGN

Segment breakdown not available.

Related Comparisons